EMGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMGEL (EMGEL).
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
| Metabolism | Metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) isoenzyme; excreted mainly in bile and feces. |
| Excretion | Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination. |
| Half-life | Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 mL/min). |
| Protein binding | 70–80%, primarily to albumin. |
| Volume of Distribution | 0.9–1.1 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Topical: systemic absorption minimal (approximately 1–5%); oral: 50–60% (first-pass metabolism); intravenous: 100%. |
| Onset of Action | Topical: clinical effect within 30–60 minutes; intravenous: immediate; oral: 30–60 minutes. |
| Duration of Action | 4–6 hours after topical or intravenous administration; 4–8 hours after oral dosing; prolonged in hepatic or renal disease. |
| Molecular Weight | 206.28 |
| Brand Substitutes | Lamivir S 150mg/30mg Tablet, Lamistar 150 mg/30 mg Tablet, Lamostad 150 mg/30 mg Tablet, Lamostad Tablet, Stadin Plus 150mg/30mg Tablet, Lamostad 150 mg/40 mg Tablet, Lamivir S 150mg/40mg Tablet |
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for topical use. |
| Liver impairment | No dosage adjustment required for topical use. |
| Pediatric use | Safety and efficacy in children <12 years not established; for children ≥12 years, apply thin layer topically twice daily. |
| Geriatric use | No specific dose adjustment; use caution due to potential skin atrophy in elderly. |
| 1st trimester | Avoid use during first trimester unless benefit outweighs risk. |
| 2nd trimester | Limited data; use only if clearly needed. |
| 3rd trimester | May cause premature closure of ductus arteriosus and oligohydramnios; avoid after 32 weeks. |
Clinical note
Comprehensive clinical and safety monograph for EMGEL (EMGEL).
| Placental transfer | High placental transfer; crosses placenta readily. |
| Breastfeeding | Excreted into breast milk in low amounts; minimal risk to infant if used topically. |
| Lactation Rating | L2 (Safer) |
■ FDA Black Box Warning
No FDA black box warning for topical erythromycin.
| Serious Effects |
Hypersensitivity to EMGEL or any componentConcurrent use of anticoagulantsActive gastric ulcerSulfonamide allergy
| Precautions | May cause irritation, burning, stinging, or dryness at application site, Use with caution in patients with known hypersensitivity to erythromycin or any macrolide antibiotic, Superinfection may occur with prolonged use, Potential for bacterial resistance with prolonged use |
| Food/Dietary | No known food interactions. Avoid alcohol as it may increase risk of gastrointestinal irritation if oral salicylates are also used. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and teeth, causing permanent discoloration and enamel hypoplasia; also associated with impaired skeletal growth and reversible inhibition of bone growth. First-trimester exposure is not associated with major malformations but may affect early bone and tooth development. Use contraindicated after first trimester. |
| Fetal Monitoring | Monitor maternal liver function, renal function, and signs of hypersensitivity. In prolonged therapy, monitor for superinfection. No specific fetal monitoring required if used only in first trimester; if inadvertently used later, fetal ultrasound for skeletal development may be considered. |
| Fertility Effects | No adverse effects on fertility reported in human studies. Animal studies show no significant reproductive toxicity at therapeutic doses. |
| Apply sparingly to affected area; avoid contact with eyes, mucous membranes, and open wounds. Monitor for systemic absorption if used on large body surface areas. Use caution in patients with renal impairment due to potential for salicylate toxicity. Do not use with other topical preparations containing methyl salicylate. |
| Patient Advice | Wash hands before and after application. · Apply only to intact skin, not on wounds or damaged skin. · Do not use with heating pads or bandages unless directed by doctor. · Avoid sun exposure to treated area as it may cause photosensitivity. · Discontinue if rash or irritation occurs and consult doctor. |